Exscientia, an AI-driven pharmatech company, and GT Apeiron Therapeutics, a company focused on novel oncology drugs, agreed to form a joint venture. “Based on what they have already achieved, Exscientia is clearly the leader in AI-driven drug discovery, and we have witnessed this first-hand in our collaboration so far.”, Mingxi Li, GT Apeiron Therapeutics President.